ES2098842T3 - Composicion farmaceutica estabilizada y disolvente estabilizante. - Google Patents

Composicion farmaceutica estabilizada y disolvente estabilizante.

Info

Publication number
ES2098842T3
ES2098842T3 ES94115180T ES94115180T ES2098842T3 ES 2098842 T3 ES2098842 T3 ES 2098842T3 ES 94115180 T ES94115180 T ES 94115180T ES 94115180 T ES94115180 T ES 94115180T ES 2098842 T3 ES2098842 T3 ES 2098842T3
Authority
ES
Spain
Prior art keywords
solvent
pharmaceutical composition
anion
content
stabilized pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94115180T
Other languages
English (en)
Inventor
Shreerham Narahari Agharkar
Uday S Gogate
Thomas Cavanak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22433231&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2098842(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ES2098842T3 publication Critical patent/ES2098842T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)

Abstract

UNA COMPOSICION FARMACEUTICA ESTABILIZADA QUE CONTIENE PACLITAXEL, TENIPOSIDO, CAMPTOTECINA U OTRO AGENTE ANTINEOPLASTICO SUSCEPTIBLE DE DEGRADACION DURANTE EL ALMACENAMIENTO ES PRODUCIDO USANDO UN SISTEMA DISOLVENTE QUE CONTIENE UN BAJO CONTENIDO DE ANION CARBOXILATO. EL SISTEMA DISOLVENTE ES UNA MEZCLA DE ETANOL Y UN ACEITE DE RICINO POLIOXIETILADO. EL ACEITE DE RICINO POLIOXIETILADO ES TRATADO CON UN ACIDO O PUESTO EN CONTACTO CON ALUMINA PARA REDUCIR EL CONTENIDO DE ANION CARBOXILATO DEL DISOLVENTE. EL BAJO CONTENIDO DE ANION CARBOXILATO DEL DISOLVENTE PROPORCIONA AMPLIA DURACION ALMACENADO Y MENORES CANTIDADES DE DEGRADACION DE SUB-PRODUCTOS.
ES94115180T 1993-09-29 1994-09-27 Composicion farmaceutica estabilizada y disolvente estabilizante. Expired - Lifetime ES2098842T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12802693A 1993-09-29 1993-09-29

Publications (1)

Publication Number Publication Date
ES2098842T3 true ES2098842T3 (es) 1997-05-01

Family

ID=22433231

Family Applications (2)

Application Number Title Priority Date Filing Date
ES94115180T Expired - Lifetime ES2098842T3 (es) 1993-09-29 1994-09-27 Composicion farmaceutica estabilizada y disolvente estabilizante.
ES09402047A Withdrawn ES2095802A1 (es) 1993-09-29 1994-09-29 Composicion farmaceutica estabilizada y solvente de estabilizacion.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES09402047A Withdrawn ES2095802A1 (es) 1993-09-29 1994-09-29 Composicion farmaceutica estabilizada y solvente de estabilizacion.

Country Status (28)

Country Link
US (1) US5504102A (es)
EP (1) EP0645145B1 (es)
JP (1) JP3447386B2 (es)
KR (1) KR100515631B1 (es)
CN (1) CN1140297C (es)
AT (1) ATE149843T1 (es)
AU (1) AU686651B2 (es)
BE (1) BE1007987A5 (es)
BR (1) BR1100361A (es)
CA (1) CA2132936C (es)
CY (1) CY2035A (es)
CZ (2) CZ287358B6 (es)
DE (1) DE69402022T2 (es)
DK (1) DK0645145T3 (es)
ES (2) ES2098842T3 (es)
FI (1) FI115825B (es)
GR (1) GR3023583T3 (es)
HK (1) HK96797A (es)
HU (1) HU217962B (es)
IL (1) IL111065A (es)
IT (1) IT1279383B1 (es)
NO (1) NO308447B1 (es)
NZ (1) NZ264526A (es)
PL (1) PL176826B1 (es)
RU (1) RU2107500C1 (es)
SG (1) SG50479A1 (es)
TW (1) TW406020B (es)
ZA (1) ZA947482B (es)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2224200T3 (es) * 1992-11-27 2005-03-01 Mayne Pharma (Usa) Inc. Composicion inyectable estable de paclitaxel.
US20030133955A1 (en) * 1993-02-22 2003-07-17 American Bioscience, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US20030068362A1 (en) * 1993-02-22 2003-04-10 American Bioscience, Inc. Methods and formulations for the delivery of pharmacologically active agents
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6537579B1 (en) 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US6753006B1 (en) * 1993-02-22 2004-06-22 American Bioscience, Inc. Paclitaxel-containing formulations
US5610173A (en) * 1994-01-07 1997-03-11 Sugen, Inc. Formulations for lipophilic compounds
US6335356B1 (en) 1994-01-07 2002-01-01 Sugen, Inc. Method of treating a patient by parenteral administration of a lipophilic compound
US5631287A (en) * 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
US6011062A (en) * 1994-12-22 2000-01-04 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
NL9500340A (nl) * 1995-02-22 1996-10-01 Yew Tree Pharmaceuticals B V Gestabiliseerde paclitaxel-oplossing en farmaceutisch preparaat dat deze oplossing bevat.
US5726181A (en) * 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
US6774278B1 (en) 1995-06-07 2004-08-10 Cook Incorporated Coated implantable medical device
DE19536165A1 (de) * 1995-09-28 1997-04-03 Basf Ag Verfahren zur Reinigung von alkoxylierten Fetten
US6245805B1 (en) * 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
US6964946B1 (en) 1995-10-26 2005-11-15 Baker Norton Pharmaceuticals, Inc. Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
WO1997023208A1 (en) * 1995-12-21 1997-07-03 Genelabs Technologies, Inc. Taxane composition and method
US6576636B2 (en) * 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
US5795909A (en) 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
KR100358934B1 (ko) * 1996-09-13 2003-01-29 주식회사한국신약 탁솔을함유한주사용약제조성물
BR9713661A (pt) * 1996-12-30 2000-10-24 Battelle Memorial Institute Formulação e método para o tratamento de neoplasmas por inalação
US6458373B1 (en) * 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US6316479B1 (en) 1997-05-19 2001-11-13 Sugen, Inc. Isoxazole-4-carboxamide compounds active against protein tryosine kinase related disorders
BE1011216A3 (fr) * 1997-06-13 1999-06-01 Thissen En Abrege L T B Lab Forme pharmaceutique pour l'administration de paclitaxel, procede de preparation d'une composition de paclitaxel prete a l'emploi et utilisation de cette composition.
US5925776A (en) * 1997-12-24 1999-07-20 Schein Pharmacetical, Inc. Polyethoxylated castor oil, process of making the same and formulations thereof
US7030155B2 (en) * 1998-06-05 2006-04-18 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US5922754A (en) * 1998-10-02 1999-07-13 Abbott Laboratories Pharmaceutical compositions containing paclitaxel
AU1214400A (en) * 1998-10-20 2000-05-08 Ben Venue Laboratories, Inc. Process for purification of solvents useful in the preparation of pharmaceuticalcompositions
US6017948A (en) * 1998-10-30 2000-01-25 Supergen, Inc. Water-miscible pharmaceutical compositions
US6071952A (en) * 1998-12-02 2000-06-06 Mylan Pharmaceuticals, Inc. Stabilized injectable pharmaceutical compositions containing taxoid anti-neoplastic agents
US6040330A (en) * 1999-01-08 2000-03-21 Bionumerik Pharmaceuticals, Inc. Pharmaceutical formulations of taxanes
US7235583B1 (en) 1999-03-09 2007-06-26 Luitpold Pharmaceuticals, Inc., Fatty acid-anticancer conjugates and uses thereof
US6828346B2 (en) * 1999-10-25 2004-12-07 Supergen, Inc. Methods for administration of paclitaxel
US6136846A (en) 1999-10-25 2000-10-24 Supergen, Inc. Formulation for paclitaxel
CA2404370A1 (en) * 2000-03-24 2001-10-04 Baker Norton Pharmaceuticals, Inc. Taxane-based compositions and methods of use
AU2001253336A1 (en) 2000-04-10 2001-10-23 Teva Pharmaceutical Industries Ltd. Method 0f administration of paclitaxel-plasma protein formulation
ES2390066T3 (es) 2000-05-12 2012-11-06 Samyang Biopharmaceuticals Corporation Procedimiento para la preparación de micelas poliméricas mediante separación de fase de un copolímero en bloque
US7217770B2 (en) 2000-05-17 2007-05-15 Samyang Corporation Stable polymeric micelle-type drug composition and method for the preparation thereof
AU2001279168A1 (en) * 2000-08-02 2002-02-13 Atossa Healthcare, Inc. Bimodal emulsions of taxanes and butyrate polyalcohol esters
CN1116875C (zh) * 2000-10-19 2003-08-06 南京振中生物工程有限公司 紫杉醇脂质组合物及其制备方法
US6410059B1 (en) * 2000-10-20 2002-06-25 Council Of Scientific And Industrial Research Pharmaceutical composition containing cow urine distillate and an antibiotic
PL203300B1 (pl) 2000-10-31 2009-09-30 Akad Medyczna Stabilna postać farmaceutyczna leku przeciwnowotworowego oraz sposób wytwarzania stabilnej postaci farmaceutycznej leku przeciwnowotworowego
DE60136490D1 (de) 2000-11-09 2008-12-18 Neopharm Inc Sn-38-lipidkomplexe und verfahren zu ihrer verwendung
EP1337273A2 (en) * 2000-11-28 2003-08-27 Transform Pharmaceuticals, Inc. Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof
US7169819B2 (en) 2000-12-05 2007-01-30 Childrens Hospital Los Angeles Pharmaceutical compositions of fenretinide having increased bioavailability and methods of using the same
US7115565B2 (en) 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
PL207720B1 (pl) * 2001-01-25 2011-01-31 Bristol Myers Squibb Co Sposób przygotowania preparatu farmaceutycznego i jego zastosowanie, farmaceutyczny produkt oraz sposób wytwarzania kompozycji farmaceutycznej
US8552054B2 (en) 2001-03-23 2013-10-08 Luitpold Pharmaceuticals, Inc. Fatty amine drug conjugates
JP4634694B2 (ja) * 2001-03-23 2011-02-16 ルイトポルド・ファーマシューティカルズ・インコーポレーテッド 脂肪アルコール薬物複合体
DE10115740A1 (de) * 2001-03-26 2002-10-02 Ulrich Speck Zubereitung für die Restenoseprophylaxe
AU2002303210A1 (en) 2001-04-06 2002-10-21 Cytorex Biosciences, Inc. Pharmacologically active strong acid solutions
WO2003030864A1 (en) * 2001-05-29 2003-04-17 Neopharm, Inc. Liposomal formulation of irinotecan
KR100774366B1 (ko) 2001-09-10 2007-11-08 주식회사 중외제약 파클리탁셀 주사제 조성물
KR20030023369A (ko) * 2001-09-13 2003-03-19 한국과학기술연구원 화학색전용 파클리탁셀 유성 조성물, 그의 제형 및 제조방법
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
US6710195B2 (en) * 2001-11-26 2004-03-23 Supergen, Inc. Method for preparing and using polyoxyethylated castor oil in pharmaceutical compositions
AU2002357012A1 (en) * 2001-11-27 2003-06-10 Transform Pharmaceuticals, Inc. Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof
IL163666A0 (en) 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Active agent delivery systems and methods for protecting and administering active agents
AU2003230691A1 (en) * 2002-03-20 2003-10-08 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
US20080220075A1 (en) * 2002-03-20 2008-09-11 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
CZ294371B6 (cs) * 2002-06-10 2004-12-15 Pliva - Lachema, A. S. Stabilizovaná farmaceutická kompozice na bázi polyoxyethylovaného ricinového oleje a způsob její přípravy
JP4454019B2 (ja) * 2002-07-15 2010-04-21 アルコン，インコーポレイテッド 眼薬送達のための生体侵食性フィルム
US20060030578A1 (en) * 2002-08-20 2006-02-09 Neopharm, Inc. Pharmaceutically active lipid based formulation of irinotecan
WO2004035032A2 (en) * 2002-08-20 2004-04-29 Neopharm, Inc. Pharmaceutical formulations of camptothecine derivatives
DE10244847A1 (de) * 2002-09-20 2004-04-01 Ulrich Prof. Dr. Speck Medizinische Vorrichtung zur Arzneimittelabgabe
US20040122081A1 (en) * 2002-11-08 2004-06-24 Gogate Uday Shankar Pharmaceutical compositions and methods of using taxane derivatives
US20050054716A1 (en) * 2002-11-08 2005-03-10 Gogate Uday Shankar Pharmaceutical compositions and methods of using taxane derivatives
US20060263327A1 (en) * 2003-03-19 2006-11-23 Gerhard Eidenhammer Method for the production of a stable injectable formulation made of difficult to dissolve antineoplastic active substances
RU2236852C1 (ru) * 2003-06-23 2004-09-27 Закрытое акционерное общество "ДЕСКО" Средство для ингибирования репродукции оболоченных вирусов, способ его получения, фармацевтическая композиция и способ ингибирования вирусных инфекций
EP1648988A1 (en) * 2003-07-24 2006-04-26 Dabur Research Foundation Process for the purification of non-ionic solvents for stabilized injectable pharmaceutical formulations
US20050016926A1 (en) * 2003-07-24 2005-01-27 Dabur Research Foundation Stabilized formulation
US7311901B2 (en) 2003-10-10 2007-12-25 Samyang Corporation Amphiphilic block copolymer and polymeric composition comprising the same for drug delivery
EP1694660B1 (en) 2003-12-12 2009-04-08 Quiral Quimica Do Brasil Process for the preparation of anhydrous and hydrated active pharmaceutical ingredients (apis); stable pharmaceutical compositions prepared from the same and uses of said compositions
EP1694242B1 (en) * 2003-12-17 2014-04-16 Bionumerik Pharmaceuticals, Inc. Process for making pharmaceutical 7-(2-trimethylsilylethyl) camptothecin formulations
JP4433918B2 (ja) * 2004-07-15 2010-03-17 コニカミノルタエムジー株式会社 画像形成方法
KR100651728B1 (ko) * 2004-11-10 2006-12-06 한국전자통신연구원 정착기를 갖는 전자 소자용 화합물 및 이를 포함하는 전자소자와 이들의 제조 방법
GT200500310A (es) 2004-11-19 2006-06-19 Compuestos organicos
US7361683B2 (en) * 2004-11-24 2008-04-22 Yung Shin Pharm. Ind., Co., Ltd Paclitaxel aqueous injection solution and methods for preparing the same
SA06270147B1 (ar) 2005-06-09 2009-12-22 نوفارتيس ايه جي عملية لتخليق 5-(مثيل–1h–إيميدازول–1-يل )–3-(ثلاثي فلـورو مثيل)–بنزامـين
CN100548274C (zh) * 2006-01-12 2009-10-14 永信药品工业股份有限公司 紫杉醇水性注射液及其制备方法
US8242165B2 (en) * 2006-10-26 2012-08-14 Creighton University Mucoadhesive nanoparticles for cancer treatment
KR20100100949A (ko) 2008-01-08 2010-09-15 브리스톨-마이어스 스큅 컴퍼니 증식성 질환의 치료를 위한 튜불린 조정제와 항-ｃｔｌａ４ 항체의 조합물
CN101939001B (zh) * 2008-02-20 2012-06-20 埃科特莱茵药品有限公司 用于治疗卵巢癌的含有紫杉醇的组合
DE102008059201A1 (de) * 2008-11-27 2010-06-02 GÖPFERICH, Achim, Prof. Dr. In situ präzipitierende Arzneistofflösungen
EP2204167A1 (en) 2009-01-05 2010-07-07 Azad Pharma AG Pharmaceutical microemulsion for preventing supramolecular aggregation of amphiphilic molecules
LT2769737T (lt) 2009-07-20 2017-06-26 Bristol-Myers Squibb Company Anti-ctla4 antikūno derinys su etopozidu, skirtas sinerginiam proliferacinių ligų gydymui
AR093275A1 (es) 2010-03-17 2015-05-27 Centro De Excelencia En Productos Y Procesos De Cordoba (Ceprocor) Una composicion farmaceutica soluble en agua que comprende al menos una sustancia terapeuticamente activa de caracteristicas hidrofobicas y al menos un compuesto seleccionado entre los sialoglicoesfingolipidos, los glicoesfingolipidos o una mezcla de sialoglicoesfingolipidos y glicoesfingolipidos
WO2012063182A1 (en) * 2010-11-08 2012-05-18 Cadila Pharmaceuticals Limited Pharmaceutical composition of taxoids
WO2014028704A1 (en) * 2012-08-15 2014-02-20 Yung Shin Pharm. Ind. Co., Ltd. Stable pharmaceutical formulation of cabazitaxel
WO2014123935A1 (en) * 2013-02-05 2014-08-14 1Globe Health Institute Llc Biodegradable and clinically-compatible nanop articles as drug delivery carriers
EP2777691A1 (en) * 2013-03-14 2014-09-17 Pharmachemie B.V. Taxoid - Purification of Liquid Excipients
WO2016005962A2 (en) * 2014-07-11 2016-01-14 Dr. Reddy’S Laboratories Limited Stable liquid formulations of cyclophosphamide and processes
US10849916B2 (en) 2014-07-11 2020-12-01 Dr. Reddys Laboratories Limited Stable liquid formulations of cyclophosphamide and its impurities
AR100034A1 (es) 2015-01-30 2016-09-07 Consejo Nac De Investig Científicas Y Técnicas (Conicet) Una composición farmacéutica soluble en agua que comprende, al menos, una sustancia terapéuticamente activa y, al menos, una sustancia con capacidad para formar micelas
CN116328361A (zh) * 2023-03-23 2023-06-27 四川汇宇制药股份有限公司 稳定的紫杉醇溶液及其制备方法和用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR830002614B1 (ko) * 1980-04-14 1983-05-30 후로인도 산교오 가부시끼 가이샤 활성화된 의약조성물의 제법
JPS61152621A (ja) * 1984-12-27 1986-07-11 Lion Corp 液状透明口腔用組成物
RO92831B1 (ro) * 1985-07-29 1988-01-01 Viorica Dobrescu Procedeu de purificare a polietilenglicolilor
HU201567B (en) * 1988-07-21 1990-11-28 Gyogyszerkutato Intezet Process for production of intravenous medical compositions containing cyclosphorin
JPH02196789A (ja) * 1989-01-25 1990-08-03 Sankyo Co Ltd リゾキシン類化合物の安定化法
FR2678833B1 (fr) 1991-07-08 1995-04-07 Rhone Poulenc Rorer Sa Nouvelles compositions pharmaceutiques a base de derives de la classe des taxanes.
JP2598206B2 (ja) * 1992-07-17 1997-04-09 ツヤック株式会社 蛋白繊維品のハイグラル・エクスパンションの安定化法
ES2224200T3 (es) * 1992-11-27 2005-03-01 Mayne Pharma (Usa) Inc. Composicion inyectable estable de paclitaxel.
KR100371062B1 (ko) * 1992-11-27 2003-04-21 에프.에이치.포울딩 앤드 컴퍼니 리미티드 안정성이향상된주사가능한택솔조성물및이를제형화하는방법

Also Published As

Publication number Publication date
HUT68687A (en) 1995-07-28
ZA947482B (en) 1995-05-15
CY2035A (en) 1998-02-20
HU217962B (hu) 2000-05-28
NO943583D0 (no) 1994-09-27
DE69402022D1 (de) 1997-04-17
BR1100361A (pt) 2000-07-18
US5504102A (en) 1996-04-02
PL176826B1 (pl) 1999-07-30
CZ287485B6 (cs) 2000-12-13
AU7427394A (en) 1995-04-13
CA2132936C (en) 1999-06-29
CN1107367A (zh) 1995-08-30
CN1140297C (zh) 2004-03-03
FI944448A0 (fi) 1994-09-26
JP3447386B2 (ja) 2003-09-16
CZ234994A3 (en) 1995-04-12
ITRM940621A0 (it) 1994-09-28
GR3023583T3 (en) 1997-08-29
NZ264526A (en) 1996-10-28
ATE149843T1 (de) 1997-03-15
SG50479A1 (en) 1998-07-20
KR950007872A (ko) 1995-04-15
IL111065A0 (en) 1994-12-29
EP0645145A3 (en) 1995-05-24
DE69402022T2 (de) 1997-07-17
PL305240A1 (en) 1995-04-03
FI115825B (fi) 2005-07-29
HK96797A (en) 1997-08-08
CA2132936A1 (en) 1995-03-30
IL111065A (en) 2003-03-12
IT1279383B1 (it) 1997-12-10
HU9402776D0 (en) 1994-12-28
RU2107500C1 (ru) 1998-03-27
NO943583L (no) 1995-03-30
ITRM940621A1 (it) 1996-03-28
NO308447B1 (no) 2000-09-18
TW406020B (en) 2000-09-21
RU94037231A (ru) 1996-09-27
ES2095802A1 (es) 1997-02-16
DK0645145T3 (da) 1997-04-07
EP0645145B1 (en) 1997-03-12
JPH07179362A (ja) 1995-07-18
AU686651B2 (en) 1998-02-12
CZ287358B6 (en) 2000-11-15
BE1007987A5 (fr) 1995-12-05
FI944448L (fi) 1995-03-30
EP0645145A2 (en) 1995-03-29
KR100515631B1 (ko) 2005-12-08

Similar Documents

Publication Publication Date Title
ES2095802A1 (es) Composicion farmaceutica estabilizada y solvente de estabilizacion.
GB2288978A (en) Stabilized medicinal aerosol solution formulations
ES549814A0 (es) Un procedimiento para preparar una crema antibacteriana, aplicable por via topica
FI842915A0 (fi) Farmaceutiskt medel foer behandling av diabetes.
ES2079943T3 (es) Composiciones acuosas en aerosol para la pulverizacion del cabello que tienen un contenido relativamente bajo en compuestos organicos volatiles.
GR3030528T3 (en) Viscoelastic compositions of fluorinated organic compounds
KR840006126A (ko) 약학 조성물의 안정화 방법
ATE268590T1 (de) Pharmazeutische emulsion enthaltend sorbinsäure, na-edta und borsäure
RU94010496A (ru) Ноотропное средство и лекарственный состав ноотропного средства
KR850004384A (ko) 치약 조성물
KR890012960A (ko) 결정성 β-락탐 용매화물
KR960705565A (ko) 테르페나딘과 이부프로펜의 안정한 약제학적 조성물(A stable pharmaceuitical composition of terfenadine and ibuprofen)
FR2236821A1 (en) Styrene stabilise. by addn. of water - during or after distn., to prevent discoloration during transport or storage
JPS5742620A (en) Novel antiulcer agent
KR930004460A (ko) 에이(a) 87689 화합물
TW252042B (en) Injectable pharmaceutical composition containing piroxicam potassium
KR890002182A (ko) 주사제용 세파만돌 나페이트 제제의 안정화 방법
KR900015762A (ko) 냉장고용 탈취제 조성물
KR900002773A (ko) 소염제 카비놀로이미다졸
KR900000081A (ko) 트리암테렌의 약학적 액제

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 645145

Country of ref document: ES